Reckitt reiterates target after forecast-beating quarter

Like-for-like (LFL) sales growth, excluding the pharmaceuticals division, was slightly ahead of expectations at household goods giant Reckitt Benckiser in the first quarter of 2012.

Net revenue rose 3%, or 4% at constant exchange rates, to £2,357m, some way ahead of market expectations of £2,180m. LFL sales, excluding Reckitt Benckiser Pharmaceuticals (RBP), was 4%, versus expectations of a year-on-year increase of 3.8%.

MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

RB Pharmaceuticals saw revenue increase by 7% (+6% at constant exchange rates) to £167m. Good market growth in the US was not fully reflected in the net revenue growth, Reckitt said, due to dilution from continued strong film penetration and Medicaid rebates which are now being accrued at the new higher levels.

"RBP continues to make very good progress with the patient preferred Suboxone

sublingual film now at 53% market volume share, up from 48% at the end of 2011," Kapoor said.

The Cillit Bang maker reiterated its full year target of like-for-like net revenue growth, excluding RBP, of two percentage points above the market growth rate of 1-2%. "We also expect to maintain full year operating margins [excluding RBP]," the group said.

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.